Precision in Neuroscience
IXICO (ixico.com) scores 81 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, Technology brands, in the 74th percentile of 6664 Healthcare brands.
IXICO is a UK-based neuroscience company founded in 2004 and headquartered in London. It provides AI-powered neuroimaging and biomarker analysis services for central nervous system (CNS) clinical trials, functioning as an imaging Contract Research Organisation (iCRO). The company supports global pharmaceutical and biotech firms, as well as scientific consortia and non-profit research organizations, in the discovery, development, and delivery of treatments for neurological diseases through precision imaging biomarker analytics.
| Brand Name | IXICO |
|---|---|
| Domain | ixico.com |
| Industry | Healthcare, Technology |
| Founded | 2004 |
| Headquarters | London |
| Main Competitors | Clario (90/100), IQVIA (85/100), ICON plc (84/100), Icometrix (79/100), Cortechs.ai (75/100), QMENTA (77/100) |
Moz Domain Authority 36/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
IXICO has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "IXICO is a neuroscience company delivering AI-powered neuroimaging and biomarker analysis for CNS clinical trials. Trusted by global pharma and biotech to accelerate drug developme…" (Meta description: 25 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: HubSpot.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram, GitHub; no detected presence on Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is IXICO?", Claude could identify the brand as of September 2026. IXICO is a UK-based healthcare technology company that specializes in imaging analytics for clinical trials, particularly in neurodegenerative diseases like Huntington's, Alzheimer's, and multiple sclerosis. They provide medical imaging biomarker services and AI-driven analysis t Best known for Imaging biomarker analysis and AI-based image analytics for neurodegenerative disease clinical trials.
When asked "Best brands similar to IXICO?", Claude would recommend IXICO as of September 2026. If someone asked about companies specializing in imaging biomarkers for CNS clinical trials, IXICO is a recognized niche player worth mentioning.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
IXICO's main competitors in Healthcare: Clario (90/100), IQVIA (85/100), ICON plc (84/100), Icometrix (79/100), Cortechs.ai (75/100).
Sources: Brand Analyzer scan
IXICO offers AI-powered neuroimaging analysis and precision imaging biomarker services for CNS clinical trials. As an imaging Contract Research Organisation (iCRO), it provides biomarker analytics and clinical trial operations support to aid in the discovery, development, and delivery of treatments for neurological diseases.
Sources: IXICO official site
IXICO is a UK-based neuroscience company founded in 2004 and headquartered in London. It operates as an imaging Contract Research Organisation (iCRO), specializing in AI-powered neuroimaging and biomarker analysis for central nervous system (CNS) clinical trials.
Sources: IXICO official site
IXICO has limited AI-search visibility, scoring 48/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 22, recommendation 52). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: IXICO official site
IXICO was founded in 2004. IXICO operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
IXICO is headquartered in London. IXICO operates in the Healthcare category.
Sources: Wikidata
IXICO combines AI-powered neuroimaging technology with clinical trial operations expertise to deliver biomarker analytics for CNS drug development. It provides imaging biomarker insights that support the discovery, development, and delivery of treatments for neurological diseases, serving as an end-to-end imaging Contract Research Organisation for pharmaceutical and biotech clients.
Sources: IXICO official site
IXICO scores 52/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: IXICO official site
IXICO's services are used by global pharmaceutical companies, biotech firms, scientific consortia, and non-profit organizations engaged in neurological disease research and CNS drug development programmes.
Sources: IXICO official site
IXICO can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: IXICO official site
IXICO is known for its expertise in AI-powered neuroimaging and biomarker analysis specifically tailored to CNS clinical trials. It has built a reputation over roughly two decades as a specialized imaging Contract Research Organisation (iCRO) trusted by global pharmaceutical and biotech companies for neurological disease research.
Sources: IXICO official site
IXICO scores 48/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
IXICO has a limited AI-visibility profile at 48/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (63/100) and its weakest is trust (22/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: a low Moz Domain Authority of 36/100, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify IXICO from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to IXICO: iRhythm (81/100), iReliev (81/100), Forma (81/100), Monument (81/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.